BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 24838331)

  • 1. Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing.
    Lin MT; Mosier SL; Thiess M; Beierl KF; Debeljak M; Tseng LH; Chen G; Yegnasubramanian S; Ho H; Cope L; Wheelan SJ; Gocke CD; Eshleman JR
    Am J Clin Pathol; 2014 Jun; 141(6):856-66. PubMed ID: 24838331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of amplicon-based next generation DNA sequencing for diagnostic gene mutation profiling in oncopathology.
    Sie D; Snijders PJ; Meijer GA; Doeleman MW; van Moorsel MI; van Essen HF; Eijk PP; Grünberg K; van Grieken NC; Thunnissen E; Verheul HM; Smit EF; Ylstra B; Heideman DA
    Cell Oncol (Dordr); 2014 Oct; 37(5):353-61. PubMed ID: 25209392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of targeted next-generation sequencing (NGS) and real-time PCR in the detection of EGFR, KRAS, and BRAF mutations on formalin-fixed, paraffin-embedded tumor material of non-small cell lung carcinoma-superiority of NGS.
    Tuononen K; Mäki-Nevala S; Sarhadi VK; Wirtanen A; Rönty M; Salmenkivi K; Andrews JM; Telaranta-Keerie AI; Hannula S; Lagström S; Ellonen P; Knuuttila A; Knuutila S
    Genes Chromosomes Cancer; 2013 May; 52(5):503-11. PubMed ID: 23362162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.
    Borràs E; Jurado I; Hernan I; Gamundi MJ; Dias M; Martí I; Mañé B; Arcusa A; Agúndez JA; Blanca M; Carballo M
    BMC Cancer; 2011 Sep; 11():406. PubMed ID: 21943394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Next generation MUT-MAP, a high-sensitivity high-throughput microfluidics chip-based mutation analysis panel.
    Schleifman EB; Tam R; Patel R; Tsan A; Sumiyoshi T; Fu L; Desai R; Schoenbrunner N; Myers TW; Bauer K; Smith E; Raja R
    PLoS One; 2014; 9(3):e90761. PubMed ID: 24658394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of next generation sequencing technologies in comparison to current diagnostic gold standards for BRAF, EGFR and KRAS mutational analysis.
    McCourt CM; McArt DG; Mills K; Catherwood MA; Maxwell P; Waugh DJ; Hamilton P; O'Sullivan JM; Salto-Tellez M
    PLoS One; 2013; 8(7):e69604. PubMed ID: 23922754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue.
    Gailey MP; Stence AA; Jensen CS; Ma D
    Cancer Cytopathol; 2015 Jan; 123(1):30-9. PubMed ID: 25186473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next-generation sequencing analysis of lung and colon carcinomas reveals a variety of genetic alterations.
    Chevrier S; Arnould L; Ghiringhelli F; Coudert B; Fumoleau P; Boidot R
    Int J Oncol; 2014 Sep; 45(3):1167-74. PubMed ID: 24990411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS and BRAF mutation analysis in routine molecular diagnostics: comparison of three testing methods on formalin-fixed, paraffin-embedded tumor-derived DNA.
    Heideman DA; Lurkin I; Doeleman M; Smit EF; Verheul HM; Meijer GA; Snijders PJ; Thunnissen E; Zwarthoff EC
    J Mol Diagn; 2012; 14(3):247-55. PubMed ID: 22425762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
    Do H; Krypuy M; Mitchell PL; Fox SB; Dobrovic A
    BMC Cancer; 2008 May; 8():142. PubMed ID: 18495026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid clinical mutational testing of
    Van Haele M; Vander Borght S; Ceulemans A; Wieërs M; Metsu S; Sagaert X; Weynand B
    J Clin Pathol; 2020 Jan; 73(1):35-41. PubMed ID: 31296605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consistency and reproducibility of next-generation sequencing in cytopathology: A second worldwide ring trial study on improved cytological molecular reference specimens.
    Pisapia P; Malapelle U; Roma G; Saddar S; Zheng Q; Pepe F; Bruzzese D; Vigliar E; Bellevicine C; Luthra R; Nikiforov YE; Mayo-de-Las-Casas C; Molina-Vila MA; Rosell R; Bihl M; Savic S; Bubendorf L; de Biase D; Tallini G; Hwang DH; Sholl LM; Vander Borght S; Weynand B; Stieber D; Vielh P; Rappa A; Barberis M; Fassan M; Rugge M; De Andrea CE; Lozano MD; Lupi C; Fontanini G; Schmitt F; Dumur CI; Bisig B; Bongiovanni M; Merkelbach-Bruse S; Büttner R; Nikiforova MN; Roy-Chowdhuri S; Troncone G;
    Cancer Cytopathol; 2019 May; 127(5):285-296. PubMed ID: 31021538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reporting tumor molecular heterogeneity in histopathological diagnosis.
    Mafficini A; Amato E; Fassan M; Simbolo M; Antonello D; Vicentini C; Scardoni M; Bersani S; Gottardi M; Rusev B; Malpeli G; Corbo V; Barbi S; Sikora KO; Lawlor RT; Tortora G; Scarpa A
    PLoS One; 2014; 9(8):e104979. PubMed ID: 25127237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.
    Lewandowska MA; Jóźwicki W; Żurawski B
    Mol Diagn Ther; 2013 Jun; 17(3):193-203. PubMed ID: 23606169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-Generation Sequencing (NGS) Methods Show Superior or Equivalent Performance to Non-NGS Methods on
    Surrey LF; Oakley FD; Merker JD; Long TA; Vasalos P; Moncur JT; Kim AS
    Arch Pathol Lab Med; 2019 Aug; 143(8):980-984. PubMed ID: 30865489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
    Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
    Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Next-Generation Sequencing, Quantitative PCR, and Sanger Sequencing for Mutation Profiling of EGFR, KRAS, PIK3CA and BRAF in Clinical Lung Tumors.
    Gao J; Wu H; Shi X; Huo Z; Zhang J; Liang Z
    Clin Lab; 2016; 62(4):689-96. PubMed ID: 27215089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant Improvement in Detecting BRAF, KRAS, and EGFR Mutations Using Next-Generation Sequencing as Compared with FDA-Cleared Kits.
    Ma W; Brodie S; Agersborg S; Funari VA; Albitar M
    Mol Diagn Ther; 2017 Oct; 21(5):571-579. PubMed ID: 28639239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002.
    Couraud S; Vaca-Paniagua F; Villar S; Oliver J; Schuster T; Blanché H; Girard N; Trédaniel J; Guilleminault L; Gervais R; Prim N; Vincent M; Margery J; Larivé S; Foucher P; Duvert B; Vallee M; Le Calvez-Kelm F; McKay J; Missy P; Morin F; Zalcman G; Olivier M; Souquet PJ;
    Clin Cancer Res; 2014 Sep; 20(17):4613-24. PubMed ID: 25013125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.